ARTICLE
Volume 10,Issue 7
12 August 2024
Rapamycin Potentiates the Antitumor Effect of 5-Fluorouracil in Colon Cancer by Enhancing Autophagy
Xiaoming Tian ,
Youjun He ,
Tao Hao
Show Less
1
Feicheng City People’s Hospital, Shandong, 271000, China,
2
Department of Colorectal Hernia Surgery, Binzhou Medical University Hospital, Shandong, 256600, China,
JCNR 2024 , 8(7), 152–160;
https://doi.org/10.26689/jcnr.v8i7.7867
© 2024 by the Authors. Licensee Whioce Publishing, Singapore. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution 4.0 International License ( https://creativecommons.org/licenses/by/4.0/ )
Abstract
Objective: To investigate whether the mTOR inhibitor rapamycin can enhance the growth suppression effect of 5-fluorouracil (5-FU) on colon cancer cells. Methods: CCK8 assays were used to examine cell survival. Flow cytometry and Western blotting were employed to detect cell proliferation, apoptosis, and related markers. Results: The combination of rapamycin and 5-FU exhibited greater cytotoxicity in cells compared to rapamycin or 5-FU alone. Notably, cells in the G0/G1 phase increased while cells in the S phase decreased in the combination group, consistent with changes in the levels of Cyclin D1 and PCNA. Rapamycin enhanced 5-FU-induced apoptosis in vitro by inducing caspase-dependent apoptosis, which is Bax/Bcl-2 related. Conclusion: The combination of rapamycin and 5-FU showed a significant synergistic anticancer effect by enhancing autophagy. This study supports that the combination of rapamycin with 5-FU is an effective and feasible approach for colorectal cancer treatment.
References
Ogata Y, Matono K, Tsuda H, et al., 2015, Randomized Phase II Study of 5-Fluorouracil Hepatic Arterial Infusion With or Without Antineoplastons as An Adjuvant Therapy After Hepatectomy for Liver Metastases From Colorectal Cancer. PLoS One, 10(3): e0120064. https://doi.org/10.1371/journal.pone.0120064
Noordhuis P, Holwerda U, Van der Wilt CL, et al., 2004, 5-Fluorouracil Incorporation into RNA and DNA in Relation to Thymidylate Synthase Inhibition of Human Colorectal Cancers. Ann Oncol, 15(7): 1025–1032. https://doi.org/10.1093/annonc/mdh264
Hammond WA, Swaika A, Mody K, 2016, Pharmacologic Resistance in Colorectal Cancer: A Review. Ther Adv Med Oncol, 8(1): 57–84. https://doi.org/10.1177/1758834015614530
Sticz T, Molnar A, Danko T, et al., 2019, The Effects of Different mTOR Inhibitors in EGFR Inhibitor Resistant Colon Carcinoma Cells. Pathol Oncol Res, 25(4): 1379–1386. https://doi.org/10.1007/s12253-018-0434-4
Pandurangan AK, 2013, Potential Targets for Prevention of Colorectal Cancer: A Focus on PI3K/Akt/mTOR and Wnt Pathways. Asian Pac J Cancer Prev, 14(4): 2201–2205. https://doi.org/10.7314/apjcp.2013.14.4.2201
Francipane MG, Lagasse E, 2014, mTOR Pathway in Colorectal Cancer: An Update. Oncotarget, 5(1): 49–66. https://doi.org/10.18632/oncotarget.1548
Suh Y, Afaq F, Khan N, et al., 2010, Fisetin Induces Autophagic Cell Death Through Suppression of mTOR Signaling Pathway in Prostate Cancer Cells. Carcinogenesis, 31(8): 1424–1433. https://doi.org/10.1093/carcin/bgq115
Pandurangan AK, Ismail S, Esa NM, et al., 2018, Inositol-6 Phosphate Inhibits the mTOR Pathway and Induces Autophagy-Mediated Death in HT-29 Colon Cancer Cells. Arch Med Sci, 14(6): 1281–1288. https://doi.org/10.5114/aoms.2018.76935
Yang JW, Zhang QH, Liu T, 2018, Autophagy Facilitates Anticancer Effect of 5-Fluorouracil in HCT-116 Cells. J Cancer Res Ther, 14(Supplement): S1141–S1147. https://doi.org/10.4103/0973-1482.204898
Grassi G, Schneider A, Engel S, et al., 2005, Hammerhead Ribozymes Targeted Against Cyclin E and E2F1 Cooperate to Down-Regulate Coronary Smooth Muscle Cell Proliferation. J Gene Med, 7(9): 1223–1234. https://doi.org/10.1002/jgm.755
Choi HJ, Han JS, 2012, Overexpression of Phospholipase D Enhances Bcl-2 Expression by Activating STAT3 Through Independent Activation of ERK and p38MAPK in HeLa Cells. Biochim Biophys Acta, 1823(6): 1082–1091. https://doi.org/10.1016/j.bbamcr.2012.03.015
Cheng EH, Kirsch DG, Clem RJ, et al., 1997, Conversion of Bcl-2 to a Bax-like Death Effector by Caspases. Science, 278(5345): 1966–1968. https://doi.org/10.1126/science.278.5345.1966
Thornberry NA, Lazebnik Y, 1998, Caspases: Enemies Within. Science, 281(5381): 1312–1316. https://doi.org/10.1126/science.281.5381.1312
Adams JM, Cory S, 2007, Bcl-2-Regulated Apoptosis: Mechanism and Therapeutic Potential. Curr Opin Immunol, 19(5): 488–496. https://doi.org/10.1016/j.coi.2007.05.004
Macintosh RL, Ryan KM, 2013, Autophagy in Tumour Cell Death. Semin Cancer Biol, 23(5): 344–351. https://doi.org/10.1016/j.semcancer.2013.05.006
Piao J, Chen L, Quan T, et al., 2016, Superior Efficacy of Co-Treatment with the Dual PI3K/mTOR Inhibitor BEZ235 and Histone Deacetylase Inhibitor Trichostatin A Against NSCLC. Oncotarget, 7(37): 60169–60180. https://doi.org/10.18632/oncotarget.11109
Chen L, Jin T, Zhu K, et al., 2017, PI3K/mTOR Dual Inhibitor BEZ235 and Histone Deacetylase Inhibitor Trichostatin A Synergistically Exert Anti-Tumor Activity in Breast Cancer. Oncotarget, 8(7): 11937–11949. https://doi.org/10.18632/oncotarget.14442
Ellis L, Ku SY, Ramakrishnan S, et al., 2013, Combinatorial Antitumor Effect of HDAC and the PI3K-Akt-mTOR Pathway Inhibition in a Pten Defecient Model of Prostate Cancer. Oncotarget, 4(12): 2225–2236. https://doi.org/10.18632/oncotarget.1314
Li Q, Mou LJ, Tao L, et al., 2016, Inhibition of mTOR Suppresses Human Gallbladder Carcinoma Cell Proliferation and Enhances the Cytotoxicity of 5-Fluorouracil by Downregulating MDR1 Expression. Eur Rev Med Pharmacol Sci, 20(9): 1699–1706.
Lee KH, Hur HS, Im SA, et al., 2010, RAD001 Shows Activity Against Gastric Cancer Cells and Overcomes 5-FU Resistance by Downregulating Thymidylate Synthase. Cancer Lett, 299(1): 22–28. https://doi.org/10.1016/j.canlet.2010.07.020
Shigematsu H, Yoshida K, Sanada Y, et al., 2010, Rapamycin Enhances Chemotherapy-Induced Cytotoxicity by Inhibiting the Expressions of TS and ERK in Gastric Cancer Cells. Int J Cancer, 126(11): 2716–2725. https://doi.org/10.1002/ijc.24990
Bignell GR, Greenman CD, Davies H, et al., 2010, Signatures of Mutation and Selection in the Cancer Genome. Nature, 463(7283): 893–898. https://doi.org/10.1038/nature08768
Fu LL, Cheng Y, Liu B, 2013, Beclin-1: Autophagic Regulator and Therapeutic Target in Cancer. Int J Biochem Cell Biol, 45(5): 921–924. https://doi.org/10.1016/j.biocel.2013.02.007
Klionsky DJ, Abdelmohsen K, Abe A, et al., 2016, Guidelines for the Use and Interpretation of Assays for Monitoring Autophagy (3rd Edition). Autophagy, 12(1): 1–222. https://doi.org/10.1080/15548627.2015.1100356. Erratum in Autophagy, 12(2): 443. https://doi.org/10.1080/15548627.2016.1147886
Yang Z, Ghoorun RA, Fan X, et al., 2015, High Expression of Beclin-1 Predicts Favorable Prognosis for Patients with Colorectal Cancer. Clin Res Hepatol Gastroenterol, 39(1): 98–106. https://doi.org/10.1016/j.clinre.2014.06.014
Wu N, Zhu Y, Xu X, et al., 2018, The Anti-Tumor Effects of Dual PI3K/mTOR Inhibitor BEZ235 and Histone Deacetylase Inhibitor Trichostatin A on Inducing Autophagy in Esophageal Squamous Cell Carcinoma. J Cancer, 9(6): 987–997. https://doi.org/10.7150/jca.22861
Wang S, Gu K, 2018, Insulin-Like Growth Factor 1 Inhibits Autophagy of Human Colorectal Carcinoma Drug-Resistant Cells via the Protein Kinase B/Mammalian Target of Rapamycin Signaling Pathway. Mol Med Rep, 17(2): 2952–2956. https://doi.org/10.3892/mmr.2017.8272
Share
Back to top
Bio-Byword Scientific Publishing Pty. Ltd.
We are committed to supporting the scientific community by publishing impactful research and fostering effective communication among scientists. We continuously seek ways to accelerate scientific progress while upholding transparency and open dialogue. Our goal is to make knowledge freely and barrier‑free accessible to all.
Contact us: info@bbwpublisher.com
Level 10, 50 Clarence Street Sydney, NSW 2000 Australia